Marksans Pharma Limited (MARKSANS) Earnings Call Transcript & Summary
November 5, 2026
Earnings Call Speaker Segments
Operator
operatorLadies and gentlemen, good day, and welcome to Marksans Pharma Q2 FY '27 Earnings Conference Call hosted by Systematix Institutional Equities Limited. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Vishal Manchanda from Institutional Equities Limited. Thank you, and over to you, Mr. Manchanda.
Vishal Manchanda
analystThanks, Siddanth. On behalf of Systematix Institutional Equities, I welcome you to the Q2 FY '27 earnings call of Marksans Pharma. We thank the Marksans Pharma management for giving us an opportunity to host the call. Today, we have with us the senior management of the company represented by Mr. Mark Saldanha, Chairman and Managing Director; and Mr. Jitendra Sharma, Chief Financial Officer. I'll now hand over the call to the company management for opening remarks. Over to you, sir.
Mark Saldanha
executiveThank you, Vishal. Good afternoon, ladies and gentlemen. Thank you for joining us for Marksans Pharma Q2 and H1 FY '27 earnings conference call. We appreciate your continued interest in the company and your support. I'm pleased to share that we have delivered our strongest quarterly performance. Q2 was a record quarter for us with the revenue from operations reaching INR 940 crores, representing a year-on-year growth of 30.5%. More importantly, this growth was accompanied by strong improvement in profitability. EBITDA increased by 48.3% to INR 214 crores and our EBITDA margin expanded by 274 basis points to 22.8%. What is particularly encouraging is the breadth and quality of this performance. Our growth is not dependent on a single geography or acquisition. We have seen strong momentum across Europe, U.K. and continue to grow in North America. And the increasing traction in Australia and New Zealand helped us to achieve these numbers. Even excluding the contribution from QliniQ, our underlying business delivered a growth of approximately 25%. At the same time, we maintained a healthy profitability despite higher freight and input costs. This gives us confidence that the investments we've made in our portfolio, commercial capabilities and geographic expansions are translating into sustainable growth. Our performance also demonstrates the strength of our geographically diversified business model. North America continues to provide us with a large and resilient base, while U.K., Europe and Australia and New Zealand are emerging as increasingly meaningful growth engines. The diversification provides us with multiple avenues of growth and reduce our dependency on a single market. Let me begin with U.K. and Europe. We have seen a particularly strong performance. Revenue from this region increased by 65% to approximately INR 405 crores. As many of you can recall, FY '26 was a relatively subdued year for our U.K. business. We used this period to work on fundamentals, strengthen our portfolio, preparing new product launches and improving our market position. These efforts are now beginning to reflect in our performance. Even excluding the performance -- the contribution from the acquisitions, our business in the region grew by 49% in Q2. Alongside the growth in our existing business, we are making progress in important strategic priorities, building our own commercial infrastructure in key European markets. This will bring us closer to customers and give us better control on how we take our portfolio to the market. QliniQ in Netherlands contributed approximately INR 84 crores for the first half, while ABC and Marksans GmbH are strengthening our platform in Germany. These businesses are important building blocks of our European strategy and over time should increase the opportunity to introduce a wider portfolio and scale up our presence across the region. Turning to North America, which remains our largest market and contributed 44.8% of the revenue. We recorded our highest ever quarterly revenue of INR 421 crores, representing a growth of 8.7% year-on-year. This is encouraging performance in context of the economic environment in the U.S. market. Our order book remains healthy and continues to build, giving us confidence that as we look ahead in the coming quarters, price erosion in our prescription products, although be in single digits, we are still looking extremely optimistic in the U.S. market. In Australia and New Zealand, revenue grew by 64% to approximately INR 101 crores. We are seeing good traction from the strategy we have pursued to build branded prescription business under Nova. Our Rx division is growing at a strong pace and the growth we are now delivering in these markets is meaningfully ahead of the levels achieved in the previous year. We are encouraged by this progress and remain positive about the opportunities ahead. Our Rest of the World business remained impacted in the quarter by ongoing geopolitical distributions in the Middle East and other regions, which affected the timing of certain shipments in the region. Importantly, this was largely an operational and timing-related impact rather than a change in underlying opportunities in these markets. We continue to monitor the situation closely and as the conditions normalize, expect shipments -- activities to recover progressively. As we look into the second half and beyond, our growth priorities remain clear. We will continue to deepen our presence in the existing market, scale our new established urban platform, expand our product portfolio and selectively enter markets where we see an attractive opportunity. Our healthy order book, expanding commercial capabilities and strong financial position gives us confidence in our ability to sustain profitable growth. Importantly, we are pursuing these opportunities from a position of financial strength. Our strong cash generation and a net cash balance provide us the flexibility to continue to invest in our product pipeline and commercial capabilities while selectively evaluating acquisitions that offer a compelling strategic and financial fit. We remain disciplined in capital allocation, focused on execution and committed to creating a sustainable long-term value. With this, I hand over to Jitendra to take you through the financial performance.
Jitendra Sharma
executiveThank you, sir, and good afternoon, everyone. I will take you through the financial performance for the second quarter followed by the first half performance. Starting with Q2, total income stood at INR 958 crores, registering year-on-year growth of 29.2%. Revenue from operation was INR 940 crores at 30.5% year-on-year and 11.8% sequentially. Looking at the geographical results, North America contributed INR 421 crores, representing 44.8% of revenue. UK and Europe contributed INR 405 crores or 43% and Australia and New Zealand contributed INR 101 crores or 10.7%, while the Rest of World contributed INR 14 crores or 1.5%. Gross profit increased year-on-year by 33.6% to INR 550 crores, ahead of revenue growth. Gross margin improved by 135 basis points year-on-year to 58.5%. EBITDA increased year-on-year at 48.3% to INR 214 crores. EBITDA margin expanding by 274 basis points to 22.8%, ahead of our 20% -- 21% guidance for the year. During Q1, we benefitted from consumption of lower cost inventory. However, we are now seeing increase of inventory costs resulted in gross margin moving to 58.5% from 59.1% in the previous quarter. Notably, freight costs have nearly doubled in the current environment. Higher freight contribution, approximately INR 20 crores to the sequential increase into other expenses. There has been a slight increase in the employee cost also by approximately INR 8 crores as we continue to strengthen our team and invest in the newer markets. In addition, our German business incurred initial start-up costs of a couple of crores as we prepare these operations for the next phase. Against this backdrop, delivering a record quarterly EBITDA and maintaining an EBITDA margin of 22.8% is particularly encouraging. It reflects the operating leverage in our business and improving product and geography mix and disciplined execution across our markets. Profit before tax for the quarter was INR 194 crores, up 35.1% year-on-year. Profit after tax increased by 44.8% to INR 144 crores with a net margin of 15%. Profit after tax declined sequentially to INR 144 crores compared with INR 159 crores in Q1, primarily due to higher depreciation and amortization following the commencement of amortization on acquisition-related intangible assets, lower other income as currency movements stabilized and a higher effective tax rate of 25.8%. Moving to the first half performance. Total income stood at INR 1,825 crores, up 33.4%, while revenue from operations increased by 32.9% to INR 1,781 crores. Gross margin improved by 137 basis points to 58.8%, supported in part by the lower average cost of inventory consumed, particularly during Q1. EBITDA grew by 74.7% to INR 427 crores, with the margin expanding by 574 basis points to 24%. Profit after tax increased by 92.5% to INR 303 crores with a net margin of 16.6%. The first half PAT also benefited from the higher other income. Cash generation was another important highlight of the first half. Cash generated from operations was at INR 322 crores compared with INR 75 crores in the corresponding period last year. Cash conversion measured as operating cash flow as a percentage of EBITDA improved to 75.2% from 30.7%. After capital expenditure of INR 46 crores, free cash flow stood at INR 275 crores. We also continue to make progress in working capital management. The working capital cycle reduced to approximately 128 days in first half of the year from 138 days in FY '26. During H1, we deployed around INR 95 crores towards acquisitions and paid dividend of around INR 41 crores. Even after these outflows, our net cash position increased by INR 135 crores during the period. As of September end, cash balance and current investments stood at INR 1,124 crores. Our net cash position was therefore at INR 1,095 crores, while net worth stood at INR 3,367 crores. Our return ratios have also improved meaningfully. On a trailing 12-month basis, return on capital employed increased to 24.7% from 18.7%, while return on equity improved to 18.6% from 13.6%. For H1, R&D expenditure was 2.6% of revenue. To conclude, the first half reflected strong growth in revenue and profitability, healthy cash conversion and continued improvement in capital efficiency. Thank you. We will now be happy to take your questions.
Operator
operator[Operator Instructions] The first question comes from the line of Ahmed Madha from Unifi Capital.
Ahmed Madha
analystCongratulations on a very good set of numbers and execution. Firstly, on the U.S. side, if you look at the growth in terms of constant currency terms, it is relatively low in the first half. How should one think about it in terms of being able to penetrate more volumes in the second half? And in general, how does the order book look like? There were some comments on the consumer sentiment in U.S. How do you see the market and growth in the second half and in general for the U.S business.
Mark Saldanha
executiveObviously, seasonality being number one. A substantial amount of our portfolio is seasonal, which is obviously more tilting towards the cold season. The cold season has yet to -- they normally comes in October, November, December is the season. That said and done, obviously, when we talk of sentiments, we talk about geopolitical scenarios where we talk of inflation, crude oil, everything of that stuff, having impact on affordability in the U.S., obviously, cost going up. I think medicines are literally the last priority on everyone's mind. Obviously, food and gas becomes the top priority for everyone else. So all this coupled with seasonalities, I mean, we have grown to some extent and we will continue growing in the U.S. market. We are quite optimistic on achieving our objectives. We still believe within the next 3 years, we should reach $300 million order book status with regards to the U.S. So we're still very optimistic where U.S. is concerned.
Ahmed Madha
analystThe overall run rate is now close to almost INR 1,000 crores probably next quarter or so, you reach that. So in terms of organic capacity expansion, how do you think about it? Obviously, we have a lot of cash available. So do we go into a major CapEx cycle next year or so?
Mark Saldanha
executiveSo again, like I've said, our outlook is more longer than with immediate outlook. So we do believe we are trending and we are working -- we are working and trending towards achieving INR 5,000 crores in the next 3 years and possibly doubling our revenue from where we were last year within the next 5 years, INR 6,000-odd crores. So we are working towards that. And that would need obviously infusion of CapEx in terms of manufacturing infrastructure to support that growth phase. Today, you're right, we are trending at INR 1,000 crores a quarter, very close to INR 1,000 crores, but you can round it off INR 1,000 crores a quarter. That gives us some visibility on a INR 4,000 crore mark. So today, we don't talk about INR 4,000 crores. We are already planning for INR 5,000 crores. And for that, we are looking at opportunities in terms of expanding our infrastructure, it may be adding another manufacturing block or acquiring another plant. We are in active dialogue on both sides.
Operator
operatorThe next question comes from the line of Arun from Unifi Capital.
Arun Kumar
analystSir, congratulations on the good set of numbers. Could you explain how revenue growth looks in the other regions, particularly the U.K. With the U.K. slow base from last year's price war ending from Q4, what growth do you expect there? At an overall level, how does -- can you brief on that? Do you...
Mark Saldanha
executiveSo U.K. looks very promising, Arun and I must say it has overcome the last year's slow revenue stream. We have introduced newer products, newer launches pretty much like I've always said, you got to just wait for the business model sometimes to unfold. We had a lot of products in the pipeline. We have a lot of products under filing under registration and under approval. So as and when these approvals do happen and we are expecting quite a few approvals every quarter, they will unfold revenue streams, new revenue streams, new penetration of these molecules into the market. So U.K. is looking promising, but also Europe because we are now looking at Europe, both from a geography as well as from an expansion of our IPs that we have created. So we are exhaustively looking at creating those infrastructures to market our products across Europe. And we are seeing some good results, although it's just the start. It's been a couple of months since we are into Europe, but it's looking extremely promising. So if you ask me my outlook of U.K. and Europe, they will still continue to grow over the next couple of years and will be very important geographies to hit our objectives of INR 6,000 crores.
Arun Kumar
analystGot it, sir. And historically, H2 PAT has been higher than H1. And given that the importance of Q3 for our products, do you expect that trend to continue this year? Will H2 PAT be higher than H1, given that H1 has already benefited from the lower cost inventory and ForEx gains?
Mark Saldanha
executiveIt's a very good question, Arun. So like you rightly said, the H1 -- the first quarter obviously benefited from a lot of low cost growth, while because of the crude oil and because of everything, the cost has gone up. And while we keep depleting our stocks, we have to basically purchase new inventory. We believe we'll be range bound overall for the year. Like I've always committed, I think our performance in revenue is -- will keep growing and I'm quite confident of us setting objectives. And I think our EBITDA should be pretty much in the range bound of 21%, 22%, whatever we performed this year -- this quarter. So I do see our overall EBITDA being in that same range. The PAT -- with regards to PAT, I think besides provisions of different taxations and depreciation, I think our PAT will be pretty much in line with what is expected.
Operator
operatorThe next question comes from the line of [ Saksham Tyagi from Nestwell Advisory ].
Unknown Analyst
analystMy first question is that in the investor presentation, you have mentioned Europe to be the key growth driver in the upcoming quarters. So I just wanted an insight on that. Like how is it going to be the key growth driver in the upcoming quarters?
Mark Saldanha
executiveBecause it has got a very low pace today as we are working hard in basically generating revenue. So these all are going to add to both our revenue streams, which was not factored over last year. So definitely, it is adding to being a growth driver presently. So we are literally starting from 0 where Europe is concerned. I do see Europe over the next 3 years shaping up very well, being very prominent player -- prominent contributor to our overall scheme of objectives, like I mentioned to the previous -- to Arun previously.
Unknown Analyst
analystOkay. So it might take up to 3 years to see the visible changes, right?
Mark Saldanha
executiveWell, we are already seeing some changes. They may be small today, but they will grow every year. And we do see growth happening in ABCnow. We do see growth happening in what -- even in the QliniQ, our Netherland company. So -- and then we have -- we are looking and exploring on more M&As in Europe and we do hope to conclude a couple of them down the line, hopefully, within the next 12 months.
Unknown Analyst
analystOkay, sir. Understood. And sir, my next question is on the expansion side. Since we are aiming to expand the Indian capacity to 16 billion units per annum. So I just wanted to know how are we going to achieve that? And how much time is it going to take?
Mark Saldanha
executiveSo I think expansion will happen in 2 folds. One is within our facility, within our infrastructure that we have within the Teva plant, we are planning to add in a couple of blocks to expand dosage forms as well as some capacity debottlenecking. But we are also looking at expanding or acquiring a plant, which will give us more of -- which will basically fuel more potential of revenue as well as volumes, which is needed. So we are basically in dialogue with 2 companies today, but nothing concrete. But we are looking at basically expanding our manufacturing capabilities, hopefully, maybe which we probably need a year down the line or so, immediate a bit, but maybe a year, 1.5 years down the line.
Unknown Analyst
analystOkay. So is there any expected time line for that?
Mark Saldanha
executiveI would probably put 12 months.
Unknown Analyst
analystOkay, sir. And lastly, I wanted to know that since you have acquired 100% stake in Access Healthcare in Dubai. So can you give some color on that like how is it going? And what would be the contribution? And also, I wanted to know if there are any acquisitions lined up in the UAE region?
Mark Saldanha
executivePresently, we are looking at the geopolitical scenario. There is no M&As, acquisitions planned in the Middle East. I think Access Healthcare is holding its own right now, taking into consideration that it's been through the -- for the full year. The war has impacted the Middle East, but we are still very profitable. It's still generating enough of cash, although the revenue is extremely small in the overall context of our turnover. But it is -- we are working -- again, in the scenarios, we are working on increasing our pipeline by 10 folds. So we are busy working on filing products and trying to grow that basket as early as possible.
Operator
operatorThe next question comes from the line of [ Mihir Buha ] from Integrative Ventures and Partnerships.
Unknown Analyst
analystCongratulations on a good set of quarters. I have a couple of questions. First question is on the volume growth side, like how would be the volume for this quarter for geographies?
Mark Saldanha
executiveThe volume will be strong. It depends from where -- what volume are you talking? Are you talking from the Indian point of view? Or are you talking from the global point of view? Volume should be strong from all angles. But again, I think seasonality, we are waiting for a strong winter and we are hoping for that. But the third quarter is normally the stronger quarter for us. So we are hoping that we'll see good volumes.
Jitendra Sharma
executiveSo see our entire growth, so if you see the first half of the current year, our revenue has grown by 32.9% and a substantial part of this has come through volume growth only.
Unknown Analyst
analystOkay. Got it. And could you please give the mix between Rx and OTC for this quarter and H1?
Mark Saldanha
executiveJiten?
Jitendra Sharma
executiveYes, it was broadly very much similar. I think between 70% to 75% -- around 75% OTC and 25% will be Rx.
Operator
operatorThe next question comes from the line of [ Sandeep N. ] from MoneyGrow Assets.
Unknown Analyst
analystSo given the substantial cash balance on the book, is management considering any kind of share buyback program or any acquisition? So I just want to know more about the capital allocation.
Mark Saldanha
executiveYes. Sandeep, we are allocating a decent amount of capital with -- on 2 fronts. One is obviously CapEx and the second one is M&As. So we have been in dialogue with companies and we continue to be in dialogue with companies. So we are looking at our growth being fueled in Europe. So we do look at a couple of more M&As that may come across Europe. But again, the size may differ. Some may be small, some may be larger in size, but we look for opportunities to grow and that's where the funds are kept so that we can consummate those M&As. But till then, we are now looking at acquiring facilities in India, which we would probably need a decent amount of cash to be plowed out there on those funds. Buyback is always an option and we are -- we have discussed on this and we will continue evaluating as and when we feel that nothing else is happening, that could be a possibility also.
Operator
operator[Operator Instructions] The next question comes from the line of [ Harshil ] from ASK Wealth Advisors.
Unknown Analyst
analystCongratulations on a good set of numbers, sir. Sir, actually, in the initial part, I missed your comments on the U.S. market. So I just wanted to know how do we look at the U.S. market, especially in the context that we've got a mid-single-digit price erosion going around, which I believe could be the case going ahead also. But overall, with respect to growth prospects outlook, how should it be for the second half and probably FY '28 as we go in? Do we have any launches like any number of launches signed up? And maybe any comment on this from your side would be helpful.
Mark Saldanha
executiveWe have about -- we are filing every year, we are filing ANDAs. We have about -- I'm hoping within this next year -- within the next couple of months till March, we should be filing another 5 or 6 ANDAs. So this is a nonstop process, right? So we continue to go down that road. We are increasing our product portfolio in all directions. We are quite optimistic on the U.S. market. I know geopolitically, it was a bit of -- it was a bit in a mess from all that was created, but there is some silver lining. So we are hoping for good news. We are hoping for corrective actions to be taken. The elections -- the midterm elections was concluded. So I'm quite confident that the U.S. market will still be a growth driver. I don't think we have to evaluate it on a quarter-on-quarter basis. I think we have to look at it from a medium term to long term because a lot of investments are going in terms of filings. So if you ask me my visibility for the next 3 years, I think we are still moving towards a $300 million order book status within the next 3 years.
Unknown Analyst
analystOkay. So you're trying to say a $300 million order book kind of over the next 2 to 3 years. Is that correct, if I heard it correct?
Mark Saldanha
executiveYes, 3 years. Within the next 3 years, I do believe our order book will increase from INR 225 crores to INR 300 crores.
Unknown Analyst
analystOkay. And so it will be from INR 225 crores to INR 300 crores.
Mark Saldanha
executiveYes.
Unknown Analyst
analystOkay. That's there. And sir, I just wanted to have your this thing, on the ROW markets wherein the geopolitical issues and all are there. You did allude to in your initial comments also that you're monitoring the situation. But is there any view that you would want to share like the run rate should be as it is in first half or any meaningful -- any slight improvements you would be envisaging over there?
Mark Saldanha
executiveI see improvement. I still see us doing quite well for the emerging markets. The first half was a bit of a struggle because it affected transportation. It affected -- vessels were not -- obviously were all stuck in the Red Sea and everything there was chaos related to logistics, supply chain. I think that is slowly easing up. And I do see a better movement happening even in this month, in the last month. So I do see us making up for some lost ground. Obviously, we can't make up for 6 months, but we are making up for lost ground. And I do believe that we'll be on track, hopefully, by the end of this year and come back to what we had envisaged for these markets. We still are focusing on our filings or our product registration in these markets. So from our outlook, I mean, these are small bumps that one has to overcome because of situation which are beyond our control. But I think we don't look at it in quarters, like I mentioned, we look at it more from a long-term point of view.
Unknown Analyst
analystGot your point. So sir, about INR 25-odd crores run rate per quarter is something that we could expect towards the exit of FY '27 for the ROW markets, yet to see that or no?
Mark Saldanha
executiveIt's difficult looking at -- again, we are all hoping for a better -- if you had asked me this question maybe a quarter back, I never thought the war would last this long. I was hoping that the war would be over before the election because of the pressure of the election, but who knows? It didn't happen. So I don't have a crystal ball to predict on geopolitical scenarios. But if things ease up, then I would say, yes, I mean, very close to INR 25 crores, maybe INR 20 crores to INR 25 crores is doable.
Operator
operatorThe next question comes from the line of Mihir Damania from Fident AMC.
Mihir Damania
analystSo my first question is you alluded that you are looking at manufacturing assets in India. I wanted to get a bit more color on what exactly you are kind of looking at. So historically, you've been very strong in oral solid. So are we looking at similar assets which can give us a lot more capacity? Or are we looking at different modalities like probably going into injectables or maybe a backward integration kind of an asset, which can help us control costs better? Just wanted a bit further because you alluded that this might require a substantial amount of investment versus all the other acquisitions in the past.
Mark Saldanha
executiveYes. I mean for us, presently, whatever we are looking at different dosage forms, not injectables, but we are looking at expanding dosage forms where we believe we would foresee some constraints in terms of capacity maybe 2 years down the line. And tablets and solid -- sorry, solid oral could be a part of it also. So definitely, whatever we do, there's always solid oral around it. So -- but yes, we are looking right now at expanding manufacturing capabilities.
Mihir Damania
analystBackward integration you're not looking at API.
Mark Saldanha
executiveBackward integration as on date, looking at what's happening globally, we have just -- we are not getting into that right now.
Mihir Damania
analystAnd my second question was on the depreciation. I just wanted to get a bit more color because sequentially there has been almost like INR 6 crores, INR 7 crores depreciation increase, while [ gross ] doubled, so I understand that it's because of some intangible accounting, but I wanted to understand whether this is the run rate to kind of take for us because on 100 million -- sorry, INR 100 crore kind of an acquisition, INR 6 crore quarterly depreciation seems slightly slim, so if you get a bit more color of what depreciation we can kind of expect going ahead, that would be very helpful.
Jitendra Sharma
executiveYes, Mihir. So we have changed our accounting treatment for depreciation on intangible assets from this quarter. And earlier, we were just testing it for impairment and we were taking indefinite useful life for arriving at the impairment decision. So from this quarter, we basically are taking intangible asset as a finite useful life and we have started depreciating it over a period of 10 years. And the reason for increase in this figure was we have also started providing for depreciation on acquired intangible assets from QliniQ and ABCnow. So this impact has come largely from the acquired intangible assets also during this year.
Mihir Damania
analystSo fair to assume that this will be the going run rate for the next couple of quarters or...
Jitendra Sharma
executiveYes.
Operator
operator[Operator Instructions] The next question comes from the line of [ Akshit Shetty from Manjit Kothari Family Office ].
Unknown Analyst
analystCongratulations on the strong performance. My first question is U.S. OTC, in the second quarter of FY '27 presentation, you mentioned your ambition to double U.S. store brand OTC revenue, supported by an expanding product pipeline. And one interesting trend is that U.S. store brand are increasingly competing on product quality and innovation rather than just price. So in this changing environment are we, Marksans is strengthening its position with large retailers beyond being cost competitive manufacturer. So do you see opportunity to become a strategic product development and a supply chain partner for these retailers?
Mark Saldanha
executiveYes. Akshit, we are and we are already in some of the retailers, we already positioned there where we talk of launching first to market or we talk of innovations. So we always have dialogues with them on innovation and quite a few of our retailers, we look at us for those directions.
Unknown Analyst
analystOkay. Got it. I have one more question regarding the European region. In the same presentation, you highlighted the contribution from QliniQ in the Netherlands and the consolidation of ABCnow in Germany. So with this expanded European presence, could you explain how you plan to use this local distribution platform to introduce Marksans existing product and future launches across multiple European markets? And do you see this creating a meaningful new growth channel beyond the existing U.K. business over, say, next 3 to 5 years?
Mark Saldanha
executiveYes. The answer in one word is yes, number one. Number two is, these of ours are more and centric on the country or the geography that we've acquired them on. So when you talk of QliniQ, it is Netherlands, you talk of ABC, it's Germany. So these markets does not represent the whole of Europe, but it does represent that country. And that's where our inorganic growth strategies of M&As will continue in other countries in Europe. But they will add significant growth, both tangibly and intangibly in what we do in Europe as well as what we do in that particular country. And both countries are quite potential and Germany is a big market also.
Operator
operator[Operator Instructions] The next question comes from the line of Pranav Gupta from Value Advisors.
Pranav Gupta
analystI have a couple of questions. Firstly, Australia grew 64% year-on-year. Just wanted to understand how much of it came from the Nova division? And how do we see the next few quarters shaping up?
Mark Saldanha
executiveWell, Australia, 100% comes from Nova. We don't market anywhere else. So Nova is our subsidiary, and we market -- it's our front end. So we market all our products through them. And we see Australia growing over the next 3 years to $100 million subsidiary.
Pranav Gupta
analystNoted. And just a follow up, is our Europe target of the top line of about INR 1,000 crores in 5 years still valid?
Mark Saldanha
executiveYes.
Operator
operatorThe next question comes from the line of from [ Tanvi ] from Mera Capital.
Unknown Analyst
analystFirstly, congratulations on a great set of numbers, sir. I have a couple of questions. Firstly, I wanted to know is the INR 4,000 crores revenue target in about 2 years still on track?
Mark Saldanha
executiveI think next year, we should touch INR 4,000 crores. So I mean we are trending right now very close to INR 1,000 crores a quarter. So I think very comfortably we can say that next year, we will hit INR 4,000 crores.
Unknown Analyst
analystOkay. Secondly, I wanted to ask, since the U.K. market has grew significantly after a flat or flat year of FY '26, is it sustainable?
Mark Saldanha
executiveYes, it is sustainable. And because of the product pipelines and we can see visibility on approvals coming in, I do believe it is sustainable. So it will show growth. It's -- I mean it's not overnight going to double its revenue, but it will grow significantly well.
Unknown Analyst
analystOkay. Lastly, I just wanted to ask what is the dividend policy for FY '27 given the net cash position currently?
Mark Saldanha
executiveWe have to evaluate that. We had a lot of things on our plate right now. We've not given...
Jitendra Sharma
executiveHistorically, like 1/3 of our free cash flow generation, we have been distributing as dividend. So broadly, it will be in line with that.
Operator
operator[Operator Instructions] The next question comes from the line of Arun from Unifi Capital.
Arun Kumar
analystA question on API costs. So we have been seeing reports of API prices, especially paracetamol and ibuprofen being at elevated levels. So have prices peaked or started to cool or are they still elevated? And given Q2 gross margins of 58.5%, what should be the margin that we should expect for Q3 and Q4, closer to 58% or the usual guidance of 55% to 56%?
Mark Saldanha
executiveI'll probably maintain it at 55%, 56%. Again, Arun, these things can change very rapidly if the crude prices come down, you will see it going down, if the war goes from bad to worse, then obviously, everything is, all projections go for a toss. But we are quite optimistic on the outlook. And this is very prevalent to what's happening in the midterm elections. So we do see things cooling down a bit. And if you've seen in the last couple of days, the crude has improved a bit. So I do see that prices should cool down maybe in the next 30 days or so.
Arun Kumar
analystGot it, sir. And if prices fall, would it quickly reach a gross margin or the retailers would ask for price cuts? How does it usually happen, sir?
Mark Saldanha
executiveRetailers will not ask for a price cut, but our gross margin will increase, obviously, or will come back to its historic numbers. If we see prices -- raw material prices coming down, obviously, raw material prices go up, then like I said, everything -- all calculations have to be -- everything has to be recalculated. But we are looking at it more from a positive angle and we are working towards achieving our objectives because we know this is literally a short term, it's not sustainable. And I mean, like I said earlier in the call that I was actually hoping that the war would have ended before the midterm elections. It didn't. But I had a strong feeling that it should have, for whatever political reasons. But that said and done, we're still hoping that it will end soon.
Arun Kumar
analystGot it, sir. And one last question. I see that our lease liabilities have gone up by INR 120 crores. Is it due to consolidation of the acquisition or we have taken a new lease? Can you...
Jitendra Sharma
executiveYes, we have taken a new lease in U.K., and it has come from that geography.
Operator
operatorThe next question comes from the line of Mr. Vishal Manchanda from Institutional Equities Limited.
Vishal Manchanda
analystSo I wanted to understand if you can break up your organic growth between existing products and new launches for the year? And also if you have seen any price increase or decrease in our base portfolio?
Mark Saldanha
executiveSo Vishal, it just depends on geographies again. If you look at U.S., a substantial amount of our growth will come from organically and a small portion will come from inorganic. But if you look at U.K., a decent amount will come from new launches. And obviously, in Europe, substantial amount will come again from new launches. So Australia will also be fueled by new launches that would come. This is over and above what we are doing. So we are at a decent size. We are at a decent base. So definitely, in our strategy to hit new heights, new launches play a very important role.
Vishal Manchanda
analystBut generally, if you could kind of give an indication as to what percentage of the growth usually is the new launches that contribute like if it is 20% of the growth that comes from new launches, 10%, some...
Mark Saldanha
executiveIn U.K., it will probably be 20%. But in Europe, it will probably be higher, maybe 50%, 60%. In U.S., it will probably be 10%.
Vishal Manchanda
analystAnd the focus area for your new launches is oral dosages or oral solid dosages or you are trying to kind of get into new dosage forms?
Mark Saldanha
executiveIt is quite diversified, but we are not into injectables. So that is not the case. But as on today, the maximum portfolio is obviously oral dosage as we speak. But we are diversifying slowly, but irrespective of the diversity that we are planning, it will still be the largest segment for us.
Vishal Manchanda
analystOkay. And are we witnessing any price increases in our base portfolio?
Mark Saldanha
executiveAre you talking of finished product or are you talking about...
Vishal Manchanda
analystThe finished products.
Mark Saldanha
executiveNo, we are not witnessing any of them.
Vishal Manchanda
analystOkay. And any changes in competitive intensity? So kind of are you seeing the competitive intensity coming down? Your competitors, maybe they are facing cost challenges and you are probably seeing competition coming down over years.
Mark Saldanha
executiveYes, we do see that. But every time we see something coming down, something goes up, right? So we don't actually -- we don't pay a lot of attention to all that because we basically grow on our strength and on our strategy. So we've been growing very strategically in our portfolio as well as in our geographies that we played, we've stand out, and we're seeing good results in what we are doing. So -- but it's the nature of the beast. We'll always have competition. So if we start looking at who's doing what, we tend to get -- bowed down on that. But we do -- when we are picking our product selections on what we have to do, then we obviously do our research as to see how many players are into that market. But beyond that, we don't bother what companies basically on competition.
Vishal Manchanda
analystAnd with respect to our R&D efforts, have we identified any focus area or we are targeting products, we are just kind of trying to target products where we don't have a presence in. Is that the way that we're looking at new launches or specific areas you would have identified?
Mark Saldanha
executiveYes, R&D is focused mainly on new niche molecules, let me put it this way. And as we grow, we get into a bit more complex molecules, which may involve Para IV challenges or first-to-market type of strategies. But this is all a part and parcel of us evolving to more prominent players in those markets. So our R&D focus today is going into all development of niche molecules, molecules where a number of competitors like you say or players are less or molecules which have more complexity in formulation, that's our focus point right now.
Vishal Manchanda
analystBut is this largely focused around oral solids or you have kind of the team around nasal sprays and...
Mark Saldanha
executiveIt's on oral solids, it's on tops, it's on liquids, it's on various other segments also.
Vishal Manchanda
analystSorry.
Mark Saldanha
executiveIt's on topicals, liquids, it's on various other segments also.
Vishal Manchanda
analystGot it. All right. And all your revenues that you do comes from your own manufacturing or there is also a portion of contract manufacturing that you rely on?
Mark Saldanha
executiveNo. I mean, obviously, we have plants all over in the U.S. and U.K. and in India, most of it, I would say, 98% of it or 99% of it comes from our own plants.
Vishal Manchanda
analystOkay. I think you highlighted in your presentation a few nasal sprays you launched in Australia. I think 1 nasal spray or 2 nasal spray. So are these in-house manufactured or these are outsourced?
Mark Saldanha
executiveNo, they are not in-house, but will soon be in-house. But as of today, they are not in-house.
Vishal Manchanda
analystOkay. And with respect to the kind of you are also looking to acquire manufacturing assets. So would this be any specific dosage form that you would be looking at? Or again, it would be more oral solids related manufacturing capacities?
Mark Saldanha
executiveThere are different dosage forms we are looking based on what we believe our capacity would basically fill up and fill up fast. But irrespective, whatever dosage forms we do get into, we will always ensure there is a solid oral block in and around that place. Because at the end of the day, no dosage form comes close to the solid oral dosage forms.
Vishal Manchanda
analystUnderstood. And you highlighted like probably you're seeing some capacity constraints around oral solids. Did I interpret that correctly? Or that's not.
Mark Saldanha
executiveNo. So far, we are good for the next 2 years, 2 to 3 years, but you always want additional capacity.
Operator
operatorThe next question comes from the line of Harshil from ASK Wealth Advisors.
Unknown Analyst
analystSir, just missed out on one point actually I wanted to have your views. So on the margins front, we've done a good 23% in Q2. And towards the end of full year, we had guided somewhere around 21% or something. But sir, is there a possibility that we could kind of have something higher than 21% 27?
Mark Saldanha
executiveThere's always a possibility. But for that, you got to call the President and call off the war. It's as simple as that.
Operator
operatorLadies and gentlemen, as there are no further questions, we have reached the end of question-and-answer session. I now hand the conference over to management for closing comments.
Mark Saldanha
executiveThank you, everyone, for sparing your time -- valuable time and attending this conference call. I want to wish you a good evening and be safe. Thank you very much.
Operator
operatorThank you. On behalf of Marksans Pharma and Systematix Institutional Equities Limited, that concludes this conference. Thank you for joining us. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Marksans Pharma Limited transcript — plus 261,000+ transcripts from 13,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Marksans Pharma Limited earnings transcripts and 261,000+ others is available through the
EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Marksans Pharma Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.